Skip to main content
. Author manuscript; available in PMC: 2023 Nov 15.
Published in final edited form as: Ann Oncol. 2020 Aug 20;31(11):1526–1535. doi: 10.1016/j.annonc.2020.08.2098

Figure 1. Final OS (A) in the overall population, (B) accounting for subsequent PARP inhibitor and/or platinum therapy, or (C) accounting for subsequent PARP inhibitor only (ITT population).

Figure 1.

Figure 1.

CI, confidence interval; ITT, intent-to-treat; OS, overall survival; PARP, poly(ADP-ribose) polymerase.